Tag : ALS Program

Clinical Research, Pharma & Healthcare Financing

AL-S Pharma Phase 2 Data Shows ALS Program Benefits

Business Wire
by Business Wire05
Results supported by key neuroaxonal injury biomarkers pNfH and NfL after six months of treatment AL-S Pharma’s AP-101 is an investigational human-derived antibody therapeutic that...